PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15289836-4	2004	Nonetheless, the challenge to increase the tumor response to chemotherapy while keeping low the cardiac risk may be now met by the use of a recently introduced polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD).	Polyethylene Glycols	160-179	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	222-225	
18701868-1	2008	Pegylated liposomal doxorubicin (Doxil: PLD) is a liposome-encapsulated form of doxorubicin modified with polyethylene glycol that has been approved for the treatment of AIDS-related Kaposi"s sarcoma.	Polyethylene Glycols	106-125	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	40-43	
15717735-7	2004	In pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), this delivery system encapsulates doxorubicin within polyethylene glycol-coated liposomes, leading to promising new applications for a well-established drug.	Polyethylene Glycols	110-129	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	50-53	
15717736-1	2004	Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD]), was developed to enhance the safety and efficacy of conventional doxorubicin.	Polyethylene Glycols	32-51	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	84-87	
11938765-2	1999	Serum GPI-PLD activity was determined both qualitatively and quantitatively by PEG/dextran and triton-X-114 partitioning respectively, and some kinetic properties of its enzymatic reaction were also studied.	Polyethylene Glycols	79-82	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	6-13	
12736762-2	2003	Long-circulating polyethylene glycol-coated (PEGylated) liposomal doxorubicin (PLD) has low systemic toxicity.	Polyethylene Glycols	17-36	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	79-82	
11750714-1	2002	Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) is a new formulation of doxorubicin with peculiar pharmacokinetic and pharmacodinamic properties, a favorable toxic profile and a demonstrated activity in solid tumors.	Polyethylene Glycols	0-19	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	62-65	
10811504-2	2000	Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) has long circulation time and enhanced drug accumulation in the tumor tissues.	Polyethylene Glycols	0-19	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	62-65	
31212607-9	2019	However, PLD-PEG CATL still enhanced the higher cellular association/uptake than PEG CATL did without PLD.	Polyethylene Glycols	13-16	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	9-12	
26093057-4	2015	Mice deficient in CCL2 or CCL5 demonstrated altered clearance and tissue distribution of polyethylene glycol tagged liposomal doxorubicin (PLD) compared to control mice.	Polyethylene Glycols	89-108	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	139-142